BioCryst Pharmaceuticals (BCRX) - Research Analysts' Weekly Ratings Changes

BioCryst Pharmaceuticals (BCRX) - Research Analysts' Weekly Ratings Changes


They now have a $7.00 price target on the stock. According to Zacks, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections.



from Biotech News